National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007 Article

Comer, JS, Olfson, M, Mojtabai, R. (2010). National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007 . Journal of the American Academy of Child and Adolescent Psychiatry, 49(10), 1001-1010. 10.1016/j.jaac.2010.07.007

Open Access

cited authors

  • Comer, JS; Olfson, M; Mojtabai, R
  • Comer, Jonathan S; Olfson, Mark; Mojtabai, Ramin

sustainable development goals

abstract

  • Objective To examine patterns and recent trends in multiclass psychotropic treatment among youth visits to office-based physicians in the United States. Method Annual data from the 1996-2007 National Ambulatory Medical Care Surveys were analyzed to examine patterns and trends in multiclass psychotropic treatment within a nationally representative sample of 3,466 child and adolescent visits to office-based physicians in which a psychotropic medication was prescribed. Results There was an increase in the percentage of child visits in which psychotropic medications were prescribed that included at least two psychotropic classes. Across the 12 year period, multiclass psychotropic treatment rose from 14.3% of child psychotropic visits (1996-1999) to 20.2% (2004-2007) (adjusted odds ratio [AOR] = 1.89, 95% confidence interval [CI] = 1.22-2.94, p < .01). Among medical visits in which a current mental disorder was diagnosed, the percentage with multiclass psychotropic treatment increased from 22.2% (1996-1999) to 32.2% (2004-2007) (AOR = 2.23, 95% CI = 1.42-3.52, p < .001). Over time, there were significant increases in multiclass psychotropic visits in which ADHD medications, antidepressants, or antipsychotics were prescribed, and a decrease in those visits in which mood stabilizers were prescribed. There were also specific increases in co-prescription of ADHD medications and antipsychotic medications (AOR = 6.22, 95% CI = 2.82-13.70, p < .001) and co-prescription of antidepressant and antipsychotic medications (AOR = 5.77, 95% CI = 2.88-11.60, p < .001). Conclusions Although little is known about the safety and efficacy of regimens that involve concomitant use of two or more psychotropic agents for children and adolescents, multiclass psychotropic pharmacy is becoming increasingly common in outpatient practice. © 2010 American Academy of Child and Adolescent Psychiatry.

authors

publication date

  • October 1, 2010

published in

keywords

  • ATYPICAL ANTIPSYCHOTICS
  • BIPOLAR DISORDER
  • DOUBLE-BLIND
  • Life Sciences & Biomedicine
  • MAJOR DEPRESSIVE DISORDER
  • MEDICATION USE
  • METHYLPHENIDATE
  • OUTPATIENT TREATMENT
  • PLACEBO-CONTROLLED TRIAL
  • Pediatrics
  • Psychiatry
  • Psychology
  • Psychology, Developmental
  • RISK
  • RISPERIDONE
  • Science & Technology
  • Social Sciences
  • national trends
  • pediatric psychopharmacology
  • polypharmacy

Digital Object Identifier (DOI)

start page

  • 1001

end page

  • 1010

volume

  • 49

issue

  • 10